Articles tagged "Antilymphocyte antibodies"

2020 American Transplant Congress
Outcomes of Acute Allograft Rejection Treatment with R Anti-Thymocyte Globulin (r-ATG) One Year Post Kidney Transplant
M. Yaqub, A. Riaz, D. Mishler, O. Adebiyi, T. Taber, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Acute allograft rejection is considered one of the major causes of renal allograft dysfunction. Despite maximal anti-rejection therapy grafts may not regain baseline function.…
2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
M. Colladant¹, J. Lion², P. Saas³, S. Perruche³, D. Ducloux¹, N. Mooney², J. Bamoulid¹
¹Nephrologie, Dialyse et Transplantation, CHU de Besançon, Besancon, France, ²Equipe INSERM: Endothelium, Inflammation et Alloreactivity INSERM UMR-S 976, Paris, France, ³INSERM U1098 RIGHT, Université de Franche-Comté EFS Bourgogne Franche-Comté, Besancon, France
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…
2019 American Transplant Congress
Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients
S. Crow, R. J. Bubik, S. S. Kushwaha, K. C. Mara, R. A. Dierkhising, N. L. Pereira
Mayo Clinic, Rochester, MN
*Purpose: Post-transplant malignancy is diagnosed in approximately 18% of heart transplant (HTx) recipients and is a leading long-term cause of death among these patients. The…
2019 American Transplant Congress
Allogenic Islets Cure Diabetes Following Transplantation in Omental Pouch in a Non-Human Primate Model
J. Lei¹, H. Deng¹, K. Lee¹, C. Peters¹, G. Rickert¹, R. Ivy¹, M. Coronel², E. Yolcu³, H. Shirwan⁴, A. García⁵, J. Markmann¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Surgery, Georgia Institute of Technology, Atlanta, GA, ³Institute for Cellular Therapeutics, University of Louisville School of Medicine, louisville, KY, ⁴Department of Microbiology and Immunology, University of Louisville School of Medicine, louisville, KY, ⁵School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA
*Purpose: In the current standard clinical transplant approach, islet cells are administered intravenously into the portal system where they lodge in the liver. This approach…
2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
S. Bae, A. Massie, J. Garonzik Wang, M. McAdams DeMarco, J. Coresh, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…
2019 American Transplant Congress
Low Dose Anti-Thymocyte Globulin is Enough to Prevent Acute Cellular Rejection in Kidney Transplant
P. W. Baron¹, J. Weissman², F. Fazeli³, C. Zuppan⁴, R. Villicana³, P. Wai¹, L. Beeson⁵, M. De Vera¹
¹Surgery/Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ²Pharmacy, Loma Linda University Health, Loma Linda, CA, ³Transplantation Institute, Loma Linda University Health, Loma Linda, CA, ⁴Pathology, Loma Linda University Health, Loma Linda, CA, ⁵Center for Nutrition, Healthy Lifestyle and Disease Prevention/School of Public Health, Loma Linda University Health, Loma Linda, CA
*Purpose: Rabbit anti-thymocyte globulin (rATG) cumulative dose needed to effectively and safely prevent acute cellular rejection is unknown. This study compares the efficacy of total…
2019 American Transplant Congress
Alemtuzumab versus Antithymocyte Globulin Induction Immunosuppression in Highly Sensitized Kidney Transplant Recipients
A. Brueckner¹, E. Yanqui¹, C. Truong¹, R. Baliga², L. Bowman¹
¹Tampa General Hospital, Tampa, FL, ²Florida Kidney Physicians, Tampa, FL
*Purpose: Lymphocyte depleting agents such as rabbit anti-thymocyte globulin (rATG) and alemtuzumab are used for induction in highly sensitized (PRA ≥30%) kidney transplant recipients (KTRs).…
2019 American Transplant Congress
No Indication of Increased CMV Infection in Kidney Transplant Recipients without Pharmacological Prophylaxis Receiving a Single 3mg/kg Dose of Rabbit Anti-Thymocyte Globulin (ATG) Instead of No-Induction
M. Ivani de Paula, M. Grace Bowring, A. A. Shaffer, J. Garonzik-Wang, A. Barros Bessa, C. Rosso Felipe, M. Pontello Cristelli, A. B. Massie, J. Medina Pestana, H. Silva Junior, D. L. Segev
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Induction therapy with rabbit anti-thymocyte globulin (ATG) in patients at low immunological risk remains controversial, given increased risk of cytomegalovirus (CMV) infection*Methods: To investigate…
2019 American Transplant Congress
Comparison of Long-Term Outcomes between Alemtuzumab and Rabbit Anti-Thymocyte Globulin for Acute Kidney Allograft Rejection
M. van der Zwan, M. C. Clahsen-van Groningen, D. L. Roelen, M. W. van den Hoogen, M. Van Agteren, J. I. Roodnat, C. C. Baan, D. A. Hesselink
Erasmus MC, Rotterdam, Netherlands
*Purpose: T cell-depleting antibody therapy with rabbit anti-thymocyte globulin (rATG) is the treatment of choice for glucocorticoid-resistant, recurrent and/or severe acute kidney allograft rejection (AR).…
2019 American Transplant Congress
Case Series: Anti-Thymocyte Globulin as a Treatment for Steroid-Refractory Severe Acute Hepatitis in Children
A. L. Peters, A. Miethke, K. Campbell
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Pediatric severe acute hepatitis (SAH), when not attributed to acetaminophen toxicity, is commonly hypothesized to be caused by a non-typeable viral infection and/or immune…